Trial Profile
Phase I-II Trial of Erlotinib in Higher Risk Myelodysplastic Syndrome
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 18 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Mar 2013 Planned End Date changed from 1 Mar 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 15 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.